(Q24201220)

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine vs. placebo in patients with painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Efficacy and safety of duloxetine in patients with chronic low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

EFNS guidelines on pharmacological treatment of neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Therapy Insight: fibromyalgia--a different type of pain needing a different type of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

A retrospective pooled analysis of duloxetine safety in 23,983 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Epidemiology and treatment of neuropathic pain: the UK primary care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Pregabalin for acute and chronic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Amitriptyline for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Antidepressants for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

A cost-utility comparison of four first-line medications in painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Antidepressants for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

What do we know about duloxetine's mode of action? Evidence from animals to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Neuropathic pain: redefinition and a grading system for clinical and research purposes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Gabapentin for acute and chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine for treating painful neuropathy or chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Duloxetine for treating painful neuropathy or chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

Estimation of minimum clinically important difference for pain in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

7 January 2021

Does duloxetine safely and effectively reduce the severity of diabetic peripheral neuropathic pain?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

7 January 2021

A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

7 January 2021

An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

7 January 2021

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB3

7 January 2021